Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

AURA

Aura Biosciences Inc

Apr 30 • 11:19AM ET

7.35

Dollar change -0.15
Percentage change -2.00	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWN VTWO IWC ITOT SBIO DFAS CNCR

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.93	Insider Own	19.79%	Shs Outstand	49.35M	Perf Week	1.80%
Market Cap	363.82M	Forward P/E	-	EPS next Y	-2.06	Insider Trans	21.19%	Shs Float	39.71M	Perf Month	-5.28%
Income	-76.41M	PEG	-	EPS next Q	-0.49	Inst Own	71.82%	Short Float	6.51%	Perf Quarter	-9.37%
Sales	0.00M	P/S	-	EPS this Y	-3.90%	Inst Trans	2.17%	Short Ratio	14.14	Perf Half Y	1.38%
Book/sh	4.58	P/B	1.61	EPS next Y	-2.98%	ROA	-31.90%	Short Interest	2.58M	Perf Year	-18.69%
Cash/sh	4.57	P/C	1.61	EPS next 5Y	-	ROE	-36.26%	52W Range	5.99 - 13.50	Perf YTD	-17.04%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-16.85%	ROI	-31.48%	52W High	-45.56%	Beta	0.36
Dividend TTM	-	Quick Ratio	18.76	Sales past 5Y	0.00%	Gross Margin	-	52W Low	22.70%	ATR (14)	0.38
Dividend Ex-Date	-	Current Ratio	18.76	EPS Y/Y TTM	1.75%	Oper. Margin	0.00%	RSI (14)	47.45	Volatility	5.33% 5.10%
Employees	89	Debt/Eq	0.09	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	19.80
Option/Short	Yes / Yes	LT Debt/Eq	0.07	EPS Q/Q	4.19%	Payout	-	Rel Volume	0.16	Prev Close	7.50
Sales Surprise	-	EPS Surprise	-21.11%	Sales Q/Q	-	Earnings	Mar 27 BMO	Avg Volume	182.76K	Price	7.35
SMA20	0.46%	SMA50	-7.37%	SMA200	-17.17%	Trades		Volume	9,186	Change	-2.00%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-27-23	Initiated	Scotiabank	Sector Outperform
Apr-17-23	Resumed	BTIG Research	Buy	$38
Jul-19-22	Initiated	JMP Securities	Mkt Outperform	$26

Mar-27-24 01:53PM	AURA Stock Earnings: Aura Biosciences Beats EPS for Q4 2023 (InvestorPlace)
07:00AM	Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights (Business Wire)
Mar-17-24 05:20PM	11 Oversold Biotech Stocks To Buy Right Now (Insider Monkey)
Feb-26-24 07:00AM	Aura Biosciences to Participate in Upcoming Investor Conferences (Business Wire)
Dec-11-23 09:55AM	Wall Street Analysts Think Aura Biosciences, Inc. (AURA) Could Surge 174.29%: Read This Before Placing a Bet (Zacks) -8.46%
08:00AM	Loading…
Dec-07-23 08:00AM	Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-sar) for First-Line Treatment of Early-Stage Choroidal Melanoma (Business Wire)
Nov-23-23 09:55AM	Wall Street Analysts Believe Aura Biosciences, Inc. (AURA) Could Rally 200.75%: Here's is How to Trade (Zacks)
Nov-09-23 04:05PM	Aura Biosciences Reports Third Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights (Business Wire)
Nov-08-23 07:00AM	Aura Biosciences to Participate in Upcoming Investor Conferences (Business Wire)
Nov-06-23 10:02PM	Aura Biosciences Announces Pricing of Public Offering of Common Stock (Business Wire) -8.18%
04:08PM	Aura Biosciences Announces Proposed Public Offering of Common Stock (Business Wire)
03:00PM	Aura Biosciences Receives FDA Agreement Under Special Protocol Assessment (SPA) for CoMpass Phase 3 Clinical Trial of Belzupacap Sarotalocan (Bel-sar) in Early-stage Choroidal Melanoma (Business Wire)
Oct-31-23 04:05PM	Aura Biosciences to Present Updated Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2023 (Business Wire) +9.24%
Oct-02-23 04:05PM	Aura Biosciences Strengthens and Expands Leadership Team with Key Appointments (Business Wire) -7.47%
Aug-09-23 07:00AM	Aura Biosciences Reports Second Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights (Business Wire) -6.62%
06:07AM	Loading…
Jul-31-23 06:07AM	Owning 38% shares,institutional owners seem interested in Aura Biosciences, Inc. (NASDAQ:AURA), (Simply Wall St.)
May-24-23 04:05PM	Aura Biosciences to Participate in Upcoming Investor Conferences (Business Wire) -5.29%
May-12-23 07:00AM	Aura Biosciences to Participate in the JMP Securities Life Sciences Conference (Business Wire)
May-11-23 04:10PM	Aura Biosciences Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights (Business Wire)
May-03-23 07:52AM	Aura Biosciences, Inc. (NASDAQ:AURA) insider upped their holding earlier this year (Simply Wall St.)
Mar-15-23 04:10PM	Aura Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights (Business Wire)
11:11AM	Companies Like Aura Biosciences (NASDAQ:AURA) Are In A Position To Invest In Growth (Simply Wall St.)
Feb-16-23 10:43AM	Aura Biosciences Releases Data Presentation Of Eye Cancer Candidate (Benzinga) -7.17%
07:00AM	Aura Biosciences Announces Positive Interim Phase 2 Safety and Efficacy Data of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma with Suprachoroidal Administration (Business Wire)
Feb-10-23 06:03AM	Why Shares of Aura Biosciences Jumped This Week (Motley Fool)
Feb-09-23 07:00AM	Aura Biosciences to Participate in Upcoming Investor Conferences (Business Wire)
Dec-24-22 09:27AM	Institutional investors may adopt severe steps after Aura Biosciences, Inc.'s (NASDAQ:AURA) latest 11% drop adds to a year losses (Simply Wall St.)
Dec-16-22 09:54AM	12 Stocks Insiders are Buying Now (Insider Monkey)
Nov-30-22 08:50PM	Aura Biosciences Announces Pricing of Public Offering of Common Stock (Business Wire)
04:01PM	Aura Biosciences Announces Proposed Public Offering of Common Stock (Business Wire)
06:34AM	Loading…
Nov-24-22 06:34AM	Aura Biosciences, Inc. (NASDAQ:AURA) insider upped their holding earlier this year (Simply Wall St.)
Nov-10-22 07:00AM	Aura Biosciences Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights (Business Wire)
06:45AM	Aura Announces Global Phase 3 Trial Design with Suprachoroidal Route of Administration Based on Positive Phase 2 Interim Data of Belzupacap Sarotalocan in Early-Stage Choroidal Melanoma (Business Wire)
Nov-03-22 07:00AM	Aura Biosciences to Participate in Upcoming Investor Conferences (Business Wire)
Oct-06-22 10:12AM	Here's Why We're Not Too Worried About Aura Biosciences' (NASDAQ:AURA) Cash Burn Situation (Simply Wall St.)
Oct-04-22 07:05AM	Positive Data Presentations at AAO Annual Meeting Demonstrate Utility and Versatility of Clearside Biomedicals Proprietary Suprachoroidal Space Platform (GlobeNewswire)
Oct-03-22 01:37PM	Aura Biosciences Details Interim Data From Mid-Stage Study Of Ocular Oncology Drug (Benzinga) -19.48%
07:00AM	Aura Biosciences Announces Interim Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma Presented at AAO 2022 (Business Wire)
Sep-28-22 07:00AM	Aura Biosciences Announces First Patient Dosed in Phase 1 Study Evaluating Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer (Business Wire) +19.23%
Sep-27-22 07:00AM	Aura Biosciences to Present Ongoing Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2022 (Business Wire) +5.12%
Sep-07-22 07:00AM	Aura Biosciences to Present Phase 2 Safety Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) in Patients with Choroidal Melanoma at the ESMO 2022 Congress (Business Wire)
Sep-01-22 07:00AM	Aura Biosciences to Present Belzupacap Sarotalocan (AU-011) Data from Multiple Studies at the 22nd EURETINA Congress (Business Wire)
Aug-11-22 04:15PM	Aura Biosciences Reports Second Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights (Business Wire) -8.60%
Aug-02-22 07:00AM	Aura Biosciences to Participate at the 2022 BTIG Biotechnology Conference (Business Wire)
Jul-19-22 03:04PM	JMP Is Bullish On This Cancer Stock "Sees New Way to Treat Cancer" (Benzinga) +7.67%
Jul-17-22 08:36AM	Could The Aura Biosciences, Inc. (NASDAQ:AURA) Ownership Structure Tell Us Something Useful? (Simply Wall St.)
Jun-30-22 08:51AM	Aura's stock jumps 11% after announcing Fast Track status for its bladder cancer treatment candidate (MarketWatch) +12.73%
07:00AM	Aura Biosciences Receives FDA Fast Track Designation for Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer (Business Wire)
Jun-23-22 08:44AM	Aura Biosciences' Belzupacap Sarotalocan At Par With Plaque Radiotherapy In Eye Cancer (Benzinga) -6.00%
Jun-22-22 04:30PM	Aura Biosciences Reports Topline Data from a Retrospective Study of Belzupacap Sarotalocan (AU-011) versus Plaque Radiotherapy Supporting the Value of a Vision Preserving Therapy for the Treatment of Patients with Early-Stage Choroidal Melanoma (Business Wire)
Jun-17-22 07:00AM	Aura Biosciences to Present Updated Belzupacap Sarotalocan (AU-011) Data on Multiple Studies at the International Society of Ocular Oncology 2022 Bi-Annual Meeting (Business Wire) +6.92%
06:40AM	Bullish Aura Biosciences, Inc. (NASDAQ:AURA) investors are yet to receive a pay off on their US$716k bet (Simply Wall St.)
May-26-22 05:26PM	Aura Biosciences Announces Publication of Preclinical Data of the Combination of VDCs with Immune Checkpoint Inhibitors at the 2022 ASCO Annual Meeting (Business Wire)
May-25-22 07:00AM	Aura Biosciences to Participate in Upcoming Investor Conferences (Business Wire)
May-12-22 04:15PM	Aura Biosciences Reports First Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights (Business Wire)
May-03-22 04:05PM	Aura Biosciences Presents Preclinical Data Highlighting AU-011s Anti-Tumor Activity in Choroidal Metastasis, an Additional Ocular Oncology Indication at the 2022 ARVO Annual Meeting (Business Wire)
07:00AM	Aura Biosciences to Present at the 2022 Bank of America Healthcare Conference (Business Wire)
Apr-29-22 07:53AM	We Think Aura Biosciences (NASDAQ:AURA) Can Afford To Drive Business Growth (Simply Wall St.) +6.33%
Mar-23-22 04:15PM	Aura Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Clinical Development and Operational Highlights (Business Wire)
Mar-21-22 07:00AM	Aura Biosciences Announces Orphan Drug Designation Granted to AU-011 by European Commission for the Treatment of Uveal Melanoma (Includes Choroidal Melanoma) (Business Wire)
Mar-15-22 07:00AM	Aura Biosciences to Host Virtual Investor Day Focused on Ocular Oncology with Key Thought Leaders on March 22 (Business Wire) +8.57%
Mar-08-22 04:30PM	Aura Biosciences to Present Preclinical Data Highlighting AU011s Potential to Target a Broad Number of Tumor Types at the 2022 AACR Annual Meeting (Business Wire)
Feb-28-22 07:00AM	Aura Biosciences to Participate at the 42nd Annual Cowen Virtual Health Care Conference (Business Wire)
Feb-14-22 05:00PM	Aura Biosciences to Present Preclinical Data Demonstrating Applicability of AU-011 in Bladder Cancer at the 2022 ASCO Genitourinary Cancer Symposium (Business Wire)
Feb-09-22 08:00AM	Aura Biosciences to Participate at the 11th Annual SVB Leerink Global Healthcare Conference (Business Wire)
Feb-03-22 01:38PM	Medicxi Ventures Management (Jersey) Ltd Buys Aura Biosciences Inc (GuruFocus.com)
Jan-29-22 07:52AM	What Percentage Of Aura Biosciences, Inc. (NASDAQ:AURA) Shares Do Insiders Own? (Simply Wall St.)
Nov-24-21 04:05PM	Aura Biosciences Reports Third Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights (Business Wire) +11.36%
Nov-23-21 04:05PM	Aura Biosciences to Participate at the 4th Annual Evercore ISI HealthCONx Conference (Business Wire) -9.43%
Nov-15-21 11:00AM	Aura Biosciences Presents Final Phase 1b/2 Data for its first Virus-Like Drug Conjugate, AU-011, in Patients with Choroidal Melanoma at the American Academy of Ophthalmology 2021 Annual Meeting (Business Wire) +18.35%
Oct-28-21 09:39PM	Aura Biosciences Announces Pricing of Initial Public Offering (Business Wire)

Aura Biosciences, Inc. is a clinical-stage oncology company, which engages in developing a novel technology platform based on virus-like drug conjugates (VDCs) to target and destroy cancer cells selectively while activating the immune system to create long lasting anti-tumor immunity. The firm's product candidate belzupacap sarotalocan (AU-011) is in Phase 2 development for the first line treatment of choroidal melanoma, a vision and life-threatening form of eye cancer where standard of care radioactive treatments leave patients with major vision loss and severe comorbidities. The was founded by Elisabet de los Pinos in 2007 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
de los Pinos Elisabet	See Remarks	Jan 23 '24	Sale	7.64	15,853	121,141	161,438	Jan 24 04:20 PM
Feder Julie B	Chief Financial Officer	Jan 23 '24	Sale	7.64	6,609	50,521	62,991	Jan 24 04:18 PM
Matrix Capital Management Comp	10% Owner	Nov 09 '23	Buy	9.00	1,560,000	14,040,000	6,922,870	Nov 09 04:35 PM
Johnson David Michael	Director	Nov 08 '23	Buy	7.30	20,000	146,000	75,000	Nov 09 05:02 PM
Johnson David Michael	Director	Nov 08 '23	Buy	7.30	9,601	70,087	135,667	Nov 09 05:02 PM
Johnson David Michael	Director	Nov 07 '23	Buy	7.17	94,000	673,980	65,000	Nov 09 05:02 PM
Johnson David Michael	Director	Nov 07 '23	Buy	7.17	76,000	544,920	126,066	Nov 09 05:02 PM
Feder Julie B	Chief Financial Officer	Nov 06 '23	Option Exercise	2.74	3,900	10,686	73,500	Nov 07 06:09 PM
de los Pinos Elisabet	See Remarks	Nov 06 '23	Option Exercise	2.74	3,800	10,412	184,740	Nov 07 06:19 PM
de los Pinos Elisabet	See Remarks	Nov 06 '23	Sale	12.03	7,449	89,611	177,291	Nov 07 06:19 PM
Feder Julie B	Chief Financial Officer	Nov 06 '23	Sale	12.07	3,900	47,054	69,600	Nov 07 06:09 PM
de los Pinos Elisabet	See Remarks	Oct 30 '23	Sale	6.83	9,586	65,478	180,940	Nov 01 06:21 PM
Feder Julie B	Chief Financial Officer	Oct 30 '23	Sale	6.82	3,385	23,091	69,600	Nov 01 06:24 PM
Johnson David Michael	Director	Oct 04 '23	Buy	8.61	6,566	56,512	50,066	Oct 05 07:56 PM
Johnson David Michael	Director	Oct 03 '23	Buy	8.27	13,500	111,663	43,500	Oct 05 07:56 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AURA

Aura Biosciences Inc

Upgrade your FINVIZ experience